Perpetual Ltd Has $1.89 Million Stock Holdings in Autolus Therapeutics PLC Sponsored ADR $AUTL

Key Points

• Perpetual Ltd reduced its stake in Autolus Therapeutics PLC by 32.2%, owning approximately 829,090 shares valued at $1.89 million after selling 394,653 shares in the 2nd quarter.
• Despite the share reduction, institutional investors collectively own 72.83% of Autolus Therapeutics, indicating strong institutional interest in the company.
• Autolus Therapeutics reported earnings per share of ($0.18), exceeding analysts' estimates, with revenue of $13.50 million for the quarter.

Perpetual Ltd trimmed its stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 32.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 829,090 shares of the company's stock after selling 394,653 shares during the quarter. Perpetual Ltd owned about 0.31% of Autolus Therapeutics worth $1,890,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Jane Street Group LLC grew its stake in shares of Autolus Therapeutics by 809.4% in the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock worth $159,000 after purchasing an additional 91,222 shares during the last quarter. Armistice Capital LLC boosted its holdings in shares of Autolus Therapeutics by 19.6% during the first quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock worth $17,050,000 after purchasing an additional 1,800,000 shares during the period. Vident Advisory LLC acquired a new stake in shares of Autolus Therapeutics during the first quarter worth approximately $241,000. Tema Etfs LLC acquired a new stake in shares of Autolus Therapeutics during the first quarter worth approximately $171,000. Finally, Wellington Management Group LLP lifted its stake in Autolus Therapeutics by 6.9% in the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company's stock valued at $41,992,000 after acquiring an additional 1,746,020 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on AUTL shares. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, July 21st. Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Finally, Wells Fargo & Company dropped their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Autolus Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $9.12.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock traded down $0.05 during trading hours on Tuesday, reaching $1.34. 1,385,313 shares of the company's stock traded hands, compared to its average volume of 2,201,368. Autolus Therapeutics PLC Sponsored ADR has a fifty-two week low of $1.11 and a fifty-two week high of $5.00. The firm has a market capitalization of $355.30 million, a price-to-earnings ratio of -1.60 and a beta of 1.87. The firm's 50 day moving average is $1.91 and its 200-day moving average is $1.80.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to the consensus estimate of $12.92 million. Analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.